Chapter 19. Dementia-Related Disorders MTM Data Set
What is the most important component of an initial MTM interview with a patient or caregiver regarding dementia?
a. Dedicate sufficient time for the visit.
b. After the interview, ask the patient or caregiver, “Do you have any questions?”
c. Avoid discussing any sensitive issues such as inevitable decline, psychiatric complications (eg, depression, anxiety), or family support.
d. Do not focus on the patient’s educational or health literacy status because the MTM form is going to the primary physician.
When performing a patient assessment in a patient with dementia it is crucial to:
a. refer the patient to an assisted living facility.
b. review the current medication profile and ask about over-the-counter products and neutraceuticals.
c. avoid use of scales or inventories because their utility is limited in patients with dementia.
d. stay emotionless and focus on obtaining a detailed patient history.
What is considered a therapeutic failure that may warrant a change in cognitive medications (eg, donepezil, galantamine)?
a. No change from baseline in the MMSE scores
b. A decrease from baseline in the MMSE by 1 to 2 points in a year
c. A decrease from baseline in the MMSE by 5 points in a year
d. Loose stools during the first 3 days of cholinesterase inhibitor therapy
Which statement demonstrates proper use of living room language?
a. “You have Alzheimer disease. This is a neurocognitive disorder that will cause a deterioration of your cognitive abilities over time.”
b. “You have Alzheimer disease. This is a disease that affects your memory and the ability to take care of yourself over time.”
c. “You have Alzheimer disease. Pharmacologic treatment options include cholinesterase inhibitors and N-Methyl-D-aspartate inhibitors that work by regulating your neurotransmitters.”
d. “You have Alzheimer disease. This is a cognitive disease that can cause psychiatric conditions such as anhedonia, alogia, psychosis, and overall deterioration of your activities of daily life.”